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A B S T R A C T
Background: The association of Mehran risk score (MRS) with long-term prognosis in patients treated
with percutaneous coronary intervention (PCI) has not been fully reported. We investigated the
association between MRS and clinical outcomes in patients who underwent PCI.
Methods: Study subjects comprised 2198 patients treated with PCI from the Ibaraki Cardiovascular
Assessment Study multicenter registry, excluding patients receiving hemodialysis or who died within
7 days. We categorized them into 4 groups according to MRS (low-risk: 5; medium-risk: 6–10; high-
risk: 11–16; and very high-risk: 16). Contrast-induced acute kidney injury (CI-AKI) was deﬁned as an
increase of 0.5 mg/dL or 25% in pre-PCI serum creatinine within 1-week post procedure. We evaluated
CI-AKI and major adverse cardiac and cerebrovascular events (MACCE), and deﬁned as all-cause death,
myocardial infarction, congestive heart failure, or cerebrovascular disorder (stroke or transient ischemic
attack).
Results: A total of 192 (8.7%) patients developed CI-AKI. At multivariate analysis, odds ratio for CI-AKI
was 4.09 (95% CI: 1.72–9.17, p = 0.002) in the very high-risk group, 1.49 (95% CI: 0.89–2.42, p = 0.120) in
the high-risk group, and 1.08 (95% CI: 0.74–1.54, p = 0.693) in the medium-risk group, as compared with
the low-risk group. MACCE in the very high-risk group was more than 5-fold higher [hazard ratio (HR)
5.40, 95% CI: 2.96–9.28, p < 0.001] compared with the low-risk group and was also increased in the high-
risk (HR 3.72, CI: 2.59–5.32, p < 0.001) and medium-risk groups (HR 1.97, CI: 1.45–2.69, p < 0.001).
Kaplan–Meier analysis showed that increasing risk for MACCE was seen across the groups as MRS
increased (p < 0.001).
Conclusion: MRS might provide potentially useful information for prediction of CI-AKI and clinical
outcomes after PCI.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Contrast-induced acute kidney injury (CI-AKI) is an important
complication that can occur after percutaneous coronary inter-
vention (PCI) [1–3]. It has been associated with both short- and* Corresponding author at: Cardiovascular Division, Faculty of Medicine,
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightslong-term adverse outcomes, including the need for renal
replacement therapy, major cardiac adverse events, and mortality
[4]. Patients with chronic kidney disease (CKD), diabetes mellitus,
congestive heart failure, older age, hypotension, and anemia are at
particular risk of CI-AKI, and Mehran et al. devised a simple risk
score for prediction of CI-AKI after PCI [5]. The Mehran risk score
(MRS) is a scoring system based on comorbidities and procedural
risk factors, including hypotension, intra-aortic balloon pumping,
heart failure, age >75 years, anemia, diabetes mellitus, volume of
contrast, and renal function [5] (Table 1). Predicted incidences of
CI-AKI are reported to be 7.5%, 14%, 26.1%, and 57.3% for scores reserved.
Table 1
Parameters in Mehran risk scores.
Risk factors Integer score
Hypotension 5
IABP 5
CHF 5
Age > 75 years 4
Anemia 3
Diabetes 3
Contrast media volume 1 for each 100 cm3
eGFR 40–60 mL/min/1.73 m2 2
eGFR 20–40 mL/min/1.73 m2 4
eGFR <20 mL/min/1.73 m2 6
IABP, intra-aortic balloon pump; CHF, congestive heart failure; eGFR,
estimated glomerular ﬁltration rate.
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(very high-risk), respectively. Sgura et al. demonstrated that the
MRS can also be applied in an ST-elevation myocardial infarction
(STEMI) population and is able to predict CI-AKI development and
to discriminate between low-, medium-, high-, and very high-risk
patient subgroups for consequent poor clinical outcomes during
both short- and long-term follow-ups [6]. Prediction of long-term
clinical outcomes in patients with coronary artery disease (CAD)
treated with elective and emergent PCI except for STEMI patients is
also important as is the prediction of CI-AKI development and early
risk stratiﬁcation [7,8]. However, the association of the MRS with
long-term prognosis in patients treated with PCI has not been fully
reported. To address this issue, we investigated the association
between MRS and clinical outcomes in patients who underwent
PCI.
Materials and methods
Study design
The Ibaraki Cardiovascular Assessment Study (ICAS) registry was
designed as a retrospective multicenter observational study of CAD
in Ibaraki Prefecture, Japan. All consecutive CAD patients who
underwent PCI at 12 cooperating centers were enrolled in this
registry [9]. Study subjects are summarized in Fig. 1. A total of
2657 patients were enrolled from April 2007 to August 2010. We
excluded the patients on dialysis (n = 83), those who died within
7 days of their PCI (n = 34), and those with no information regarding
clinical outcome or serial measurement of creatinine (n = 342). The
study population thus comprised 2198 patients who were dividedFig. 1. Study ﬂow chart. PCI, percutaneous coronary intervention; Cr, creatinine.into 4 groups according to MRS: low-risk, 5 (n = 1170); medium-
risk, 6–10 (n = 755); high-risk, 11–15 (n = 233), and very high-risk,
16 (n = 40). Patients with baseline renal impairment [estimated
glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2] would
receive approximately 12 h of pre-hydration with 0.9% normal
saline at a rate of 1 mL/kg body weight per hour in the elective
setting. Saline hydration would continue during the PCI procedure
until 12 h post-PCI. In the urgent setting, hydration would be started
immediately if renal impairment had been identiﬁed. The use of
prophylaxis strategies, including N-acetylcysteine and sodium
bicarbonate, was made at the discretion of treating physicians.
This study was approved by the institutional review boards or ethics
committees of all participating institutions.
Clinical data collection
Patient demographic information, cardiovascular risk factors,
laboratory ﬁndings, angiographic ﬁndings, and PCI procedure
characteristics were recorded according to medical charts on initial
enrollment in the registry. The serum concentration of creatinine
was measured serially, before the exposure to contrast and at 24,
48, and 72 h after PCI. When the creatinine concentration was
not available for day 2 or 3, we used the value obtained within
1 week after contrast exposure. An eGFR was calculated by using
the Modiﬁcation of Diet in Renal Disease study equation modiﬁed
for the Japanese population [10]. Contrast volume used during
each PCI was recorded. The MRS was calculated on the basis of
information collected before the procedure.
Study endpoints
All follow-up data and clinical events were surveyed once a year
during the study period. Data for patients who were lost to follow
up were censored at the time of the last contact. The primary
endpoint for the present analysis was the incidence of major
adverse cardiac and cerebrovascular events (MACCE), which were
deﬁned as all-cause death, myocardial infarction, congestive heart
failure, or cerebrovascular disorder (stroke or transient ischemic
attack). Secondary endpoints included the development of CI-AKI
deﬁned as an increase in serum creatinine of more than 25% or
0.5 mg/dL from the baseline within 1 week after contrast exposure
[7]. The serum creatinine concentration was not available on day
2 or 3 for 25% of the patients, and we used the value obtained
within 1 week after contrast exposure. Additional secondary
endpoints included the individual endpoint of requiring dialysis or
all-cause death, myocardial infarction, congestive heart failure, or
cerebrovascular disorder. All deaths were conﬁrmed by medical
charts or by contacting the referring physician and/or patient’s
family, and all events were registered by the attending physicians.
Coronary angiography and PCI procedure
PCI was performed according to standard techniques. All
patients received treatment with aspirin (100 mg/day) and
clopidogrel (75 mg/day following a 300-mg loading dose). A
glycoprotein IIb/IIIa receptor inhibitor is not yet available in Japan.
Operators selected interventional devices and performed PCI
through either the radial, brachial, or femoral artery using 5–7
French catheters. A low-osmolality, non-ionic contrast agent was
used (iopamidol 350 mg I/mL; Schering AG, Berlin, Germany).
Before starting the procedure, 8000 units of heparin were given
intravenously, and the activated clotting time was maintained at
>300 s. Once the guide wire passed through the culprit lesion,
balloon dilatation or stent placement was performed. Treatment
was regarded as successful when the luminal diameter of the
target lesion increased by at least by 50%, residual stenosis was less
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ﬂow was grade 3 [11].
Statistical analysis
Continuous variables are reported as mean  SD or median and
interquartile ranges, as appropriate. The ANOVA test was used to
determine differences between mean values for parametrically and
non-parametrically distributed variables, respectively. Categorical
variables are reported as absolute values and percentages and were
analyzed by Fisher exact chi-square test. Kaplan–Meier curves were
made to describe the freedom from MACCE and all-cause death rates,
and the log-rank test was used to identify signiﬁcant differences in
unadjusted survival rate among all groups. Multivariate Cox propor-
tional hazards models were used to calculate variables predictive of
primary endpoints (MACCE) and all-cause death, and multivariate
logistic regression analysis was used to determine factors predictive of
CI-AKI. Factors identiﬁed through univariate analysis (p < 0.01) and
other variables considered likely to have important prognostic value
were tested in a multivariable Cox proportional hazards model for
association with MACCE and all-cause death during the follow-up
period. Covariates included male sex, risk factors (dyslipidemia,
hypertension), acute coronary syndrome, ejection fraction 45%, and
multivessel disease. Follow-up ﬁnished either on the day of the adverse
event or the day of the latest visit to the outpatient clinic. The Kaplan–
Meier method and log-rank test were used to compare MACCE and
all-cause death rates of the patients according to the MRS. A two-
sided p-value of <0.05 was considered to be statistically signiﬁcant
throughout the analysis. All statistical analyses were performed with
the JMP 9 software package for Macintosh (SAS Inc., Cary, NC, USA).Table 2
Baseline patient characteristics, laboratory data, and procedure-related variables.
Low (n = 1170) Medium (n = 7
Age, years 65  9 74  10
Male sex 955 (82%) 560 (74%)
Body mass index, kg/m2 24.6  3.3 24.1  3.5 
Hypertension 755 (65%) 579 (77%)
Diabetes mellitus 296 (25%) 387 (51%)
Dyslipidemia 709 (61%) 416 (55%)
Current smoker 671 (57%) 394 (52%)
Previous PCI 233 (19%) 164 (22%)
Previous CABG 62 (5.3%) 58 (7.7%)
Prior myocardial infarction 169 (14%) 119 (16%)
History of heart failure 36 (3.1%) 56 (7.4%)
History of stroke 68 (5.8%) 87 (11.5%
Acute coronary syndrome 548 (46%) 337 (45%)
Acute myocardial infarction 373 (32%) 236 (31%)
STEMI 302 (26%) 182 (24%)
Multivessel disease 308 (26%) 260 (34%)
LAD culprit 545 (46%) 315 (42%)
Systolic blood pressure, mmHg 137  24 137  26
Ejection fraction, % 60  12 58  14
Hemoglobin, g/dL 14.3  1.5 13.0  1.9 
Creatinine, mg/dL 0.80  0.19 0.93  0.28
Estimated GFR, mL/min/1.73 m2 75  17 62  19
Procedure-related variables
Contrast volume, mL 172  57 184  68
DES use 866 (74%) 536 (71%)
Stent size, mm 3.11  0.46 3.04  0.48
IABP use 0 (0%) 21 (3%)
Medication
Aspirin 1135 (97%) 714 (95%)
Beta-blocker 540 (46%) 374 (49%)
ACEI and/or ARB 685 (59%) 467 (62%)
Diuretic 148 (13%) 154 (20%)
Calcium channel blocker 289 (25%) 194 (26%)
Values are mean  SD or n (%).
ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, ang
stent; GFR, glomerular ﬁltration rate; IABP, intra-aortic balloon pump; LAD, left anterio
elevation myocardial infarction.Results
Patient characteristics
Baseline and procedural characteristics of all patients are listed
in Table 2. With the increase in MRS across the four groups, age,
serum creatinine level, contrast volume, intra-aortic balloon pump
use, diuretic use, and the percentage of patients with diabetes
mellitus, history of heart failure and stroke, acute coronary
syndrome, and multivessel disease increased, whereas body mass
index, systolic blood pressure, left ventricular ejection fraction,
hemoglobin, eGFR and the percentage of patients with dyslipide-
mia decreased.
Primary and secondary endpoints
Among the 2198 patients, 243 (11.1%) patients developed
MACCE (Table 3). At multivariate analysis (Table 4), the odds ratio
for MACCE was found to be 5.40 (95% CI: 2.96–9.28, p < 0.001) in
the very high-risk group, 3.72 (95% CI: 2.59–5.32, p < 0.001) in the
high-risk group, and 1.97 (95% CI: 1.45–2.69, p < 0.001) in the
medium-risk group, as compared with the low-risk group as
the reference standard. Kaplan–Meier analysis showed that
increasing risk for MACCE was seen across the groups as MRS
increased (p < 0.001) (Fig. 2).
A total of 192 (8.7%) patients developed CI-AKI following PCI.
When the patients were divided into 4 groups according to the
MRS, the incidence of CI-AKI gradually rose with the increase in
MRS (p < 0.001) (Fig. 3). The rate of CI-AKI in the very high-risk
group was more than 4-fold higher (OR 4.09, 95% CI: 1.72–9.17,55) High (n = 233) Very high (n = 40) p-Value
 78  10 78  9 <0.001
 151 (65%) 27 (74%) <0.001
23.6  3.7 23.8  4.2 <0.001
 179 (77%) 24 (60%) <0.001
 153 (66%) 27 (68%) <0.001
 109 (47%) 14 (35%) <0.001
 102 (44%) 18 (45%) 0.330
 46 (20%) 5 (13%) 0.430
 16 (6.8%) 2 (5.0%) 0.201
 39 (17%) 6 (15%) 0.771
 30 (12.9%) 4 (10.0%) <0.001
) 27 (11.6%) 7 (17.5%) <0.001
 107 (46%) 34 (85%) <0.001
 91 (39%) 31 (77%) <0.001
 68 (29%) 25 (63%) <0.001
 95 (41%) 22 (55%) <0.001
 108 (46%) 13 (33%) 0.068
 133  31 119 40 <0.001
 55  15 43  14 <0.001
12.0  1.8 12.2  2.5 <0.001
 1.17  0.76 1.72  1.34 <0.001
 49  18 37  14 <0.001
 188  65 191  84 <0.001
 168 (72%) 24 (60%) 0.162
 3.01  0.43 3.10  0.49 0.013
 23 (10%) 23 (57%) <0.001
 217 (93%) 38 (95%) 0.013
 105 (45%) 22 (55%) 0.315
 142 (61%) 22 (55%) 0.458
 80 (34%) 11 (28%) <0.001
 66 (28%) 7 (18%) 0.426
iotensin II receptor blocker; CABG, coronary artery bypass grafting; DES, drug-eluting
r descending artery; PCI, percutaneous coronary intervention; STEMI, ST-segment
Table 3
Primary and secondary endpoints.
Low (n = 1170) Medium (n = 755) High (n = 233) Very high (n = 40) p-Value
Primary endpoint
MACCE 73 (6.2%) 98 (12.9%) 56 (24.0%) 16 (40.0%) <0.001
Secondary endpoints
All-cause death 27 (2.3%) 43 (5.7%) 31 (13.3%) 9 (22.5%) <0.001
Cardiac death 14 (1.2%) 11 (1.5%) 13 (5.6%) 6 (15.0%) <0.001
Myocardial infarction 24 (2.1%) 11 (1.5%) 9 (3.7%) 2 (5.0%) 0.126
Congestive heart failure 17 (1.5%) 43 (5.7%) 22 (9.4%) 8 (20.0%) <0.001
Stroke 17 (1.5%) 20 (2.7%) 9 (3.9%) 0 (0.0%) 0.048
Requiring dialysis 1 (0.09%) 1 (0.13%) 7 (3.00%) 2 (5.00%) <0.001
Values are n (%). MACCE, major adverse cardiovascular and cerebrovascular events.
Table 4
Multivariate logistic analysis for primary and secondary endpoints.
MRS CI-AKI All-cause death MACCE
OR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
All patients
Low 1.00 (reference) N/A 1.00 (reference) N/A 1.00 (reference) N/A
Medium 1.08 (0.74–1.54) 0.693 2.34 (1.45–3.83) <0.001 1.97 (1.45–2.69) <0.001
High 1.49 (0.89–2.42) 0.120 5.73 (3.42–9.66) <0.001 3.72 (2.59–5.32) <0.001
Very high 4.09 (1.72–9.17) 0.002 10.8 (4.79–22.1) <0.001 5.40 (2.96–9.28) <0.001
ACS patients
Low 1.00 (reference) N/A 1.00 (reference) N/A 1.00 (reference) N/A
Medium 1.07 (0.71–1.59) 0.743 4.38 (2.19–9.53) <0.001 2.71 (1.81–4.15) <0.001
High 1.59 (0.90–2.71) 0.104 11.2 (5.42–24.9) <0.001 5.84 (3.68–9.27) <0.001
Very high 4.86 (2.31–10.0) <0.001 14.7 (5.62–37.4) <0.001 7.42 (3.94–13.3) <0.001
Stable AP patients
Low 1.00 (reference) N/A 1.00 (reference) N/A 1.00 (reference) N/A
Medium 1.82 (0.91–3.70) 0.091 1.23 (0.65–2.57) 0.462 1.42 (0.90–2.23) 0.130
High 3.49 (1.48–7.87) 0.005 2.89 (1.28–6.23) 0.012 2.50 (1.41–4.29) 0.002
Very high 8.09 (0.41–54.4) 0.134 9.14 (0.50–45.5) 0.108 4.06 (0.23–18.8) 0.259
ACS, acute coronary syndrome; AP, angina pectoris; CI-AKI, contrast-induced acute kidney injury; CI, conﬁdence interval; HR, hazard ratio; MACCE, major adverse
cardiovascular and cerebrovascular events; MRS, Mehran risk score; OR, odds ratio.
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not signiﬁcantly increased in the high-risk group (OR 1.49, CI:
0.89–2.42, p = 0.120) or the medium-risk group (OR 1.08, CI: 0.74–
1.54, p = 0.693) (Table 4). We performed multivariate logistic
analysis for CI-AKI within MRS parameters in Table 5. In the
present study, hypotension, use of intra-aortic balloon pump, and
increase of contrast media volume were signiﬁcant important
predictors of CI-AKI.
A total of 110 patients (5.0%) died from all causes during the
follow-up periods. All-cause deaths in the very high-risk group
were approximately 11-fold higher (HR 10.8, 95% CI: 4.79–22.1,Fig. 2. Kaplan–Meier curves showing freedom from major adverse cardiac and
cerebrovascular events (MACCE) based on the Mehran risk score groups (low,
medium, high, and very high risk). Log-rank test, p < 0.001.p < 0.001) than those in the low-risk group and were also
signiﬁcantly increased in the high-risk group (HR 5.73, CI: 3.42–
9.66, p < 0.001) and medium-risk group (HR 2.34, CI: 1.45–3.83,
p < 0.001) (Table 4). Kaplan–Meier analysis showed that increas-
ing risk for all-cause death was seen across the groups as MRS
increased (p < 0.001) (Fig. 4).
We also analyzed the predictive value of MRS for CI-AKI, all-
cause death and MACCE separately in either acute coronary
syndrome (ACS) or stable angina pectoris (AP) in Table 4.Fig. 3. Incidence of contrast-induced acute kidney injury (CI-AKI) stratiﬁed by
Mehran risk score.
Table 5
Multivariate logistic analysis for CI-AKI within MRS parameters in all patients.
Factors OR (95% CI) p-Value
Hypotension 2.65 (1.29–5.21) 0.009
IABP 4.57 (2.38–8.51) <0.001
CHF 1.55 (0.83–2.72) 0.165
Age > 75 years 1.15 (0.80–1.63) 0.453
Anemia 1.07 (0.99–1.17) 0.086
Diabetes 1.01 (0.73–1.38) 0.975
Contrast media volume 1.00 (1.00–1.01) 0.034
Estimated GFR 1.01 (0.99–1.01) 0.127
CI-AKI, contrast-induced acute kidney injury; CHF, congestive heart failure; CI,
conﬁdence interval; GFR, glomerular ﬁltration rate; IABP, intra-aortic balloon
pump; OR, odds ratio; MRS, Mehran risk score.
Fig. 4. Kaplan–Meier curves showing freedom from all-cause death based on the
Mehran risk score groups (low, medium, high, and very high risk). Log-rank test,
p < 0.001.
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The major ﬁndings of the present study are as follows. First, the
overall incidence of CI-AKI was 8.7% in the patients who
underwent PCI. CI-AKI in the very high-risk group was more than
4-fold higher (OR 4.09, 95% CI: 1.72–9.17, p = 0.002) when
compared with the low-risk group. Second, 243 (11.1%) patients
developed MACCE, and 110 (5.0%) patients died from all causes
during the follow-up periods. The present study showed that
increasing risk for MACCE and all-cause death was seen across
the groups as MRS increased (p < 0.001). The MRS might provide
potentially useful information for the prediction of CI-AKI and
clinical outcomes after PCI.
Risk scores for prediction of CI-AKI and clinical outcomes
There is general agreement that CKD is the most crucial risk factor
for CI-AKI and that contrast volume is also a main procedure-related
risk factor for CI-AKI [2,4,10]. The other important risk factors for CI-
AKI include age over 70 years, diabetes, congestive heart failure,
dehydration, and concurrent administration of nephrotoxic agents,
i.e. non-steroid anti-inﬂammatory drugs [2,4,12]. The mechanism
and risk of CI-AKI are multifactorial, and therefore, identiﬁcation of
patients at high risk for the development of CI-AKI is of major
importance. Brown et al. reported that the risk of developing severe
renal dysfunction after PCI in patients not undergoing dialysis may be
predicted with a risk scoring system [13]. Risk could be calculated by
adding the scores representative of the patient’s comorbidities and
looking up the score on a graph to provide the estimated risk. This
information could be used at the bedside to obtain patient-speciﬁcrisk for serious renal dysfunction (new dialysis, 2.0 mg/dL absolute
increase in creatinine, or a 50% increase in creatinine) before PCI.
The MRS is a scoring system that is useful for predicting the
development of CI-AKI in patients undergoing non-emergent and
emergent PCI [5,12]. The risks of CI-AKI and of requiring dialysis were
reported to be 7.5% and 0.04% among patients with a score of 5;
14.0% and 0.12% among patients with a score of 6–10; 26.1% and
1.09% among those with a score of 11–16; and 57.3% and 12.6%
among those with a score of 16, respectively. However, because
these risk scoring systems have not been investigated prospectively,
some specialists have pointed out the inappropriateness of using
this scoring system in the clinical setting [4]. Furthermore, the
association of the MRS after PCI with long-term adverse cardiovas-
cular and renal events is less clear. Sgura et al. demonstrated that the
MRS can be applied in a STEMI population and is able to predict
CI-AKI development and to discriminate between low-, medium-,
high-, and very high-risk patient subgroups for consequential poor
clinical outcomes during both short- and long-term follow-up
[6]. However, in STEMI patients in particular, we cannot ignore the
possibility that hemodynamic instability or co-morbidity is associat-
ed with prognosis [14]. It has not been fully evaluated whether the
MRS was developed to predict clinical outcomes only in CAD patients
treated with elective and non-elective PCI during long-term follow-
up, not including STEMI patients.
We opted to perform risk stratiﬁcation using the MRS, which
makes our study relevant and unique. It has been known that the
risks of developing CI-AKI and MACCE are signiﬁcantly higher in
patients with ACS than stable AP [15]. In addition, patient
backgrounds are substantially different between these two clinical
entities. It would be meaningful if we analyze the predictive value
of MRS for CI-AKI and MACCE separately in either ACS or stable AP.
Multivariate logistic analysis showed that increasing risk for
MACCE and all-cause death was seen across the groups as the MRS
increased in the ACS patients, whereas increasing risk for MACCE
and all-cause death was only seen in the high-risk groups in the
stable AP patients because of small numbers of patients in the very
high-risk group. The MRS seems to answer the need for an all-
round score for predicting CI-AKI, all-cause death, and MACCE in
patients treated with PCI. Multiple explanations exist as to why the
MRS might be associated with an increased risk of poor outcome.
First, patients with higher MRS have higher rates of multiple
coexisting conditions and more severe and diffuse CAD. Second,
these patients also have a high prevalence of traditional coronary
risk factors such as diabetes mellitus, hypertension, congestive
heart failure, and mechanical complications.
The risk of maintenance dialysis is signiﬁcantly lower in every
MRS group of this study in the comparison with the original MRS
paper [5]. Although the cause of the discrepancy is not clear at this
time, the smaller volume of contrast used may contribute to the
prevention of maintenance dialysis in the present study (178.6
 63.2 mL vs. 260.9  122 mL). The PCI operator tries to reduce
contrast volume in patients with impaired renal function in daily
practice. However, contrast volume used during PCI was signiﬁcantly
higher in ‘‘very high’’ group than ‘‘low’’ group in this study. The reason
for this ﬁnding may be that the very-high group included higher-risk
patients with ACS and multivessel disease.
Clinical implications
To improve long-term outcome in patients treated with PCI, our
data suggest that it would be worthwhile to make further efforts
to prevent the occurrence of CI-AKI and circulatory insufﬁciency
during PCI according to level of the MRS. In emergent PCI, it is
difﬁcult to perform pre-procedure preventive measures such as
hydration with saline and various other pre-treatments, which are
considered effective for the prevention of CI-AKI. Recently, two
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the occurrence of CI-AKI and improve short-term clinical outcomes.
Han et al. reported that patients randomized to the rosuvastatin
group (10 mg/day for 5 days) had a signiﬁcantly lower incidence of
CI-AKI than controls (2.3% vs. 3.9%, respectively; p = 0.01), and
during a 30-day follow-up, the rate of worsening heart failure
was signiﬁcantly lower in the patients treated with rosuvastatin
than that in the control group (2.6% vs. 4.3%, respectively; p = 0.02)
[16]. Leoncini et al. also showed that high-dose rosuvastatin given on
admission (40 mg on admission, followed by 20 mg/day) to statin-
naı¨ve patients with ACS who are scheduled for an early invasive
procedure can prevent CI-AKI and improve short-term clinical
outcome [17]. The effects of improving long-term clinical outcomes,
such as mortality, as well as preventing CI-AKI, should be conﬁrmed
by well-designed, randomized controlled trials.
Study limitations
Several limitations in the design of the ICAS registry should be
mentioned. First, this study was based on a non-randomized
observational design. Therefore, this might have introduced a
signiﬁcant bias in the selection of prescribed medications, even
though multiple variables were adjusted for. Our study thus is
inferior in comparative validity compared with a randomized,
controlled trial. Second, serum level of creatinine, especially in the
elderly and female populations, who have low muscle mass, is
an inexact measure of renal function. Other limitations include the
lack of data regarding other potential nephrotoxic agents, such
as non-steroidal anti-inﬂammatory drugs, in the present study.
Despite these limitations, we found that the level of the MRS was
associated with a signiﬁcant increase in the development of
CK-AKI and poor prognosis in CAD patients who underwent PCI.
Conclusions
Our observational cohort analysis showed that the MRS might
provide potentially useful information for the prediction of CI-AKI
and clinical outcomes after PCI. A well-designed, large-scale,
multicenter, randomized, controlled trial will be necessary to
conﬁrm the predictive ability of the MRS to aid in the prevention of
CI-AKI as well as the improvement in long-term clinical outcome
of PCI patients.
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